The Carcinoembryonic Antigen (CEA) market experienced substantial growth, with a size of USD 1.59 Billion in 2022, projected to reach USD 2.69 Billion by 2032, at a notable revenue CAGR of 6% throughout the forecast period. Key drivers of this growth include the escalating cancer incidence and the widespread adoption of carcinoembryonic antigen tests as an essential diagnostic tool for...